Statement by the Dengue Vaccine Initiative on the Philippines Regulatory Approval of Sanofi Pasteur’s Dengue Vaccine, Dengvaxia®

December 22, 2015 — The Philippines yesterday became the first Asian country to approve Sanofi Pasteur’s dengue vaccine, Dengvaxia®, marking the second time in less than one month that a dengue vaccine has been licensed for use in a country.

Dengue Vaccine Initiative Statement on Results of Studies on the Efficacy and Long-Term Safety of Sanofi Pasteur’s Dengue Vaccine Candidate in Dengue-Endemic Regions

WASHINGTON DC – JULY 27, 2015—A study titled “Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease” (Hadinegoro et al.), published today in The New England Journal of Medicine, assesses vaccine efficacy and interim long-term safety results of Sanofi Pasteur’s dengue vaccine candidate, CYD-TDV, across three clinical trials in dengue-endemic countries within Asia-Pacific and Latin America. This analysis marks a significant scientific milestone in Sanofi Pasteur’s efforts to develop a dengue vaccine.

Dr. In-Kyu Yoon Appointed as Director of the Dengue Vaccine Initiative

WASHINGTON, DC – July 24, 2015 – The Dengue Vaccine Initiative (DVI) a consortium comprised of the International Vaccine Institute, the Johns Hopkins University’s International Vaccine Access Center, Sabin Vaccine Institute and the World Health Organization, is delighted to announce the appointment of Dr. In-Kyu Yoon as its new Director. Dr. Yoon, former Chief of the Department of Virology, Armed Forces Research Institute Medical Sciences in Bangkok, Thailand, will lead DVI starting August, 2015.

Indonesia’s Competitiveness at risk from Neglected Diseases of Poverty

WASHINGTON, D.C. – February 27, 2014 – The control and elimination of neglected tropical diseases (NTDs) is one of the most cost-effective ways Indonesia can sustain economic growth and reduce inequality, said scientists today in an analysis published in PLOS Neglected Tropical Diseases. While Indonesia is poised to defeat NTDs by 2020, it has an opportunity to scale up national programs, integrate NTDs with other development efforts, strengthen coordination and enhance collaboration among key partners.

Uncertain budget climate threatens safety of U.S. troops, veterans

WASHINGTON, D.C. – December 26, 2013 – Current budget restrictions and the threat of future cuts jeopardize the safety and mission readiness of U.S. troops, veterans’ health, and capabilities of the U.S. military’s tropical medicine research and development (R&D), said researchers today in an editorial published in PLOS Neglected Tropical Diseases.

Dengue Vaccine Initiative awarded grant from Germany for development of new dengue vaccines in Brazil and Vietnam

SEOUL, SOUTH KOREA - The Dengue Vaccine Initiative (DVI) announced today that it has received a 1 million Euro award from the German Federal Ministry of Education and Research (BMBF), the first time it has received such a grant from Germany. The funds will be used to support the development of new dengue vaccines in collaboration with the Instituto Butantan, a biomedical research center in São Paulo, Brazil, and Vabiotech, a vaccine manufacturer in Hanoi, Vietnam.

New framework for neglected tropical diseases could unlock potential for world’s poorest people

WASHINGTON, D.C. – November 22 – A new concept and policy framework published in PLOS NTDs outlines concrete steps for the global development community as it works to synthesize health goals with economic, environmental and social priorities. The concept, “blue marble health,” emphasizes the role of the Group of 20 (G20) nations in tackling neglected tropical diseases (NTDs) to expedite poverty reduction efforts.

Pages